Nearly every private practice launch comes down to the same spreadsheet fight: speed versus control. The data shows that acquired practices usually generate revenue faster because they start with patients, staff, and payer relationships already in place. De novo practices, by contrast, often start slower but give you full authority over brand, workflow, cost structure, and long-term design. That tradeoff is not philosophical. It is mathematical.
I have seen new attendings get seduced by the wrong number. Buyers fixate on purchase price and ignore hidden operating problems. Builders obsess over avoiding goodwill and then underestimate how expensive zero patients can be. Both mistakes are costly. The real decision is a four-variable model: upfront capital, time to breakeven, patient acquisition speed, and operational risk.
Those are the metrics that matter. This article compares both paths across startup cost, cash flow trajectory, patient volume ramp, overhead structure, and valuation logic. Not theory. Decision-useful numbers.
This article is for educational purposes only, not financial, legal, or tax advice. Actual figures, financing terms, valuations, and outcomes vary materially by specialty, geography, payer mix, and execution; you should review any transaction or startup plan with qualified advisors before signing documents or borrowing capital.
Lead With the Numbers: Why This Decision Matters
A purchase usually buys time. A de novo build buys freedom. The market punishes physicians who confuse the two.
If you acquire a functioning practice, you may inherit day-one collections, recall systems, established referral channels, and active payer contracts. That often compresses ramp-up time dramatically. In many markets, that is the whole game. A faster path to stable monthly cash flow reduces the odds that working capital disappears before patient demand catches up.
De novo, though, can produce a better machine. You choose the lease, the hours, the EHR, the staffing ratios, the service mix, the patient experience, the website, and the brand. No inherited bad habits. No seller’s cousin at the front desk who somehow became “indispensable.” No obsolete scheduling workflow built for 2009.
So the question is not which option is better in the abstract. That is lazy thinking. The question is which path produces the best risk-adjusted outcome for your capital base and timeline.
What the Data Shows on Upfront Cost and Risk
The headline numbers can fool you. Buying often looks expensive because there is a purchase price attached to goodwill, charts, equipment, and earnings. De novo can look cheaper on paper because there is no seller to pay. Then reality shows up.
For an acquisition, the capital stack usually includes:
- Purchase price
- Working capital reserve
- Legal and accounting diligence
- Transition and retention costs
- Possible IT conversion
- Repairs, branding refresh, or light renovation
- Hidden liabilities if diligence is sloppy
For de novo, the typical buckets are different:
- Leasehold buildout
- Furniture, fixtures, and equipment
- EHR and practice management setup
- Licensing, permits, and credentialing lag
- Marketing and patient acquisition
- Payroll before volume matures
- Working capital reserve for a longer runway
The data shows that buying usually lowers customer acquisition cost because the hardest assets are not the chairs or the autoclave. They are trust and habits. Existing patients already know the phone number. Referring physicians already know where to send cases. Staff already understand the payer mix. That is economic value, whether people like the word goodwill or not.
Risk, however, shifts rather than disappears.
With a purchase, the main danger is legacy drag. I have reviewed deals where trailing collections looked stable until you separated the owner’s personal referral relationships from the actual practice engine. Revenue was not durable; it was owner-dependent. I have also seen “profitable” offices with bloated staffing, ancient fee schedules, poor documentation, and software nobody under age 50 wanted to touch. Those are not small nuisances. They destroy post-close performance.
With de novo, the risk is uncertainty. Slower patient volume. Delayed credentialing. Underestimated marketing. A buildout that runs late by 12 weeks and burns cash before the first patient walks in. New owners routinely under-model this. Bad move.
Debt magnifies both problems. If you finance an acquisition, a modest decline in collections can tighten debt service coverage fast. If you finance de novo, slower-than-expected volume can extend negative cash flow for quarters longer than planned. I generally tell physicians to run breakeven sensitivity under at least three assumptions: 10% below expected volume, base case, and 10% above. That simple exercise exposes fragile deals quickly. If the plan falls apart with a mild miss, the structure is bad. Full stop.
Revenue Trajectory: Time to Breakeven and Cash Flow by Year 1–3
This is where acquisition usually wins. Early revenue matters more than most first-time owners admit.
An existing practice often starts with an active patient panel, booked follow-ups, in-process claims, and known payer workflows. That means collections can begin at a meaningful level almost immediately after transition, assuming retention holds. The result is a flatter ramp and earlier stabilization. In many cases, breakeven arrives materially sooner than in de novo models.
De novo behaves differently. Month one is often little more than fixed overhead plus optimism. Month three can still feel thin. Month six is where operators start discovering whether the local demand thesis was right or fantasy. If marketing is tight, access is good, and operations are efficient, momentum builds. But that is earned growth, not inherited growth.
The data pattern is consistent:
- Acquisition starts higher
- De novo starts lower
- Acquisition usually reaches breakeven sooner
- De novo may catch up later if designed well and scaled efficiently
That catch-up matters. Starting clean can produce better overhead discipline from day one. A modern scheduling template, digital intake, lean staffing, smarter room utilization, and better service mix can improve margin over time. I have seen de novo offices outperform legacy acquisitions by year three because they were built for today’s reimbursement and labor environment, not inherited from a seller who never updated anything.
Specialty changes the curve. Primary care and pediatrics often depend heavily on local brand awareness and payer access. Procedural specialties may hinge more on referral behavior and equipment capacity. Psychiatry can scale differently than orthopedics. Dermatology does not ramp like family medicine. Geography matters too. Dense suburban markets with strong population growth can support de novo more easily than stagnant markets where patient loyalty is entrenched.
Referral dependence is another dividing line. If your specialty relies on a concentrated set of referring clinicians, buying those relationships can be powerful. If demand is more direct-to-consumer or convenience-driven, de novo may have more upside because branding, access, and online presence can move volume faster.
My bias is simple: if your runway is thin, do not romanticize the slow build. A beautiful empty office is still empty. If your capital reserve is strong and your operational instincts are better than the average seller’s, de novo becomes much more attractive.
Operational Control, Culture, and Long-Term Enterprise Value
Control has economic value. People talk about it like it is just a personality preference. It is not.
With de novo, you control:
- Brand positioning
- Office layout and patient flow
- EHR and revenue cycle systems
- Staffing model and compensation design
- Hours, access strategy, and telehealth mix
- Service lines and growth priorities
That freedom lets you build a cleaner operating model. In my experience, that usually leads to better culture too. You hire for the mission instead of inheriting a tired team clinging to old habits. Culture problems are expensive. They show up as turnover, poor patient experience, lower collections, and physician burnout.
Buying can still be the smarter play if the data is good. A practice with strong retention, stable collections, low overhead, diversified referrals, and low owner dependence is a valuable asset. You are not buying furniture. You are buying cash flow. But if the seller’s results depend on personal charisma, outdated workflows, or underpriced labor, the transferability is weak. Then the “good deal” is mostly fiction.
Long-term enterprise value depends on scalability. De novo may produce a more modern platform for future sites, ancillaries, or physician recruitment. Acquisition may provide immediate EBITDA, but integration risk is real. I have watched buyers overpay for current earnings only to spend two years replacing staff, renegotiating leases, upgrading systems, and rebuilding reputation. That is not accretive. That is cleanup.
Lifestyle matters too. Some physicians want immediate income stability and minimal market-entry friction. Buy. Others want to build a brand they actually like working in for the next decade. Build. The data can frame the decision, but your tolerance for mess, delay, and ambiguity is not a rounding error. It is central.
Due Diligence, Valuation Checks, and Common Deal Breakers
This is where bad buyers donate money to the market.
For acquisitions, I want hard diligence on a short list of metrics before anybody gets sentimental:
- Trailing 12-month collections
- Payer mix by percentage
- Accounts receivable aging
- New patient volume and retention
- Staff turnover
- Top referral sources and concentration risk
- Owner dependence in clinical production and business development
Then comes valuation. EBITDA must be normalized correctly. Add-backs are abused constantly. If the seller adds back every personal expense, family payroll oddity, and one-time cost under the sun, you do not nod politely. You test each one. Goodwill should be supported by actual transferable performance, not nostalgia.
A proper valuation checkpoint includes:
- Normalized earnings after realistic replacement costs
- Retention assumptions during transition
- Sustainability of referral patterns
- Capital expenditures needed after closing
- Whether reported overhead is artificially low because the owner underpaid staff or deferred maintenance
Legal review differs by path but is equally critical. For a purchase, examine asset purchase structure, lease assignment terms, restrictive covenants, payer contract transferability, employment agreements, and compliance exposure. For de novo, the pressure points are lease terms, buildout obligations, credentialing timelines, permits, vendor contracts, and startup financing covenants.
Deal breakers are rarely subtle:
- Declining patient volume over multiple quarters
- AR that is old, inflated, or poorly documented
- Heavy dependence on one or two referral sources
- Outdated payer contracts
- Poor charting or compliance weaknesses
- Seller representations that cannot be reconciled to statements
- Staff instability that threatens continuity after close
If a seller says, “The patients will stay because everyone loves the practice,” but cannot show retention data, assume the opposite. That sentence has emptied more buyer bank accounts than most people realize.
How to Decide: A Data-Driven Framework
Here is the framework I use. Score each path from 1 to 5 on five categories:
- Capital required
- Speed to revenue
- Operational risk
- Autonomy and control
- Long-term growth platform
Then weight those categories based on your actual priorities, not your ego. If you need stable income within 12 months, speed to revenue should carry real weight. If you are trying to create a scalable brand over 10 years, autonomy and growth platform matter more.
Run three scenarios for each option:
- Conservative
- Base case
- Optimistic
Stress-test patient volume, overhead, staffing cost, and collection lag. The data shows that one assumption usually drives the whole model: volume. A 10% miss in volume can hurt more than a modest increase in rent or software expense. That is why assumptions around referrals, patient demand, and retention deserve the most skepticism.
Profiles that tend to favor buying:
- Physicians who want faster cash flow
- Operators entering a market with entrenched referral patterns
- Owners with limited tolerance for a long ramp
Profiles that tend to favor de novo:
- Physicians who want full control
- Builders with strong capital reserves
- Clinicians who see clear inefficiencies in local competitors and believe they can out-execute them
My recommendation is blunt. Do not choose based on romance. Choose based on runway, durability of demand, and your willingness to manage operational mess. The spreadsheet should fit your life, not just your ambition.
Action steps:
- Build both models side by side
- Use conservative assumptions first
- Hire legal, accounting, and valuation advisors early
- Verify every major revenue assumption
- Pick the route that works in a downside case, not just the pretty case
That is how adults buy or build practices. The rest is wishful thinking.
